Skip Navigation

Your Environment. Your Health.

Rituximab in Dermatomyositis

Study Title:

An open label trial to evaluate the safety and efficacy of rituximab in the treatment of patients with dermatomyositis


Principal Investigator:

David Fiorentino, MD, PhD


Study Hypothesis:

B cell depletion with Rituximab will be safe and effective therapy for skin and muscle inflammation in patients with dermatomyositis


Study Design:

Open label, single center, pilot study


Types & Number of IIM Studied:

8 adult dermatomyositis patients


Entry Criteria:

  • Diagnosis of probable or definite dermatomyositis by Bohan/Peter criteria (Bohan and Peter 1975), including classic dermatologic features defined by Sontheimer's criteria
  • Active muscle disease with either elevated laboratory markers of muscle breakdown (ie. CPK >400 U/L or aldolase >8 U/L) OR a MMT modified MRC score of <85
  • Active skin disease with s DSSI>2


IMACS Core Set Measures Included:

Physician Global Activity-VAS, Patient Global Activity-VAS, Muscle Strength Testing-MMT, Functional Assessment Tools-HAQ, Laboratory-Muscle Enzymes, Extramuscular Assessment-Myositis Disease Activity Assessment Tool (MDAAT)


Other Measures Included:

Patient Pruritus Assessment, Dermatomyositis Skin Severity Index (DSSI), Skin photographs, CD19 B cell level, Safety laboratory measures (CBC, CMP, Urinalysis)


Primary Outcome:

  • Safety Endpoints
    • Incidence of treatment emergent adverse events (AE's) including infections, infusion reactions and disease progression.
    • Safety assessment will include physical examination with vital signs, routine blood work (hematology and chemistry) and immunological testing.
  • Primary Efficacy Endpoint: Partial remission (PR) at 24 weeks, defined as:
    • At least a 50% reduction in creatine phosphokinase (CPK) if baseline values are >2x upper limits of normal OR
    • 50% improvement of manual muscle strength test (MMT) using the modified Medical Research Council (MRC) scale (Daniels and Worthingham 1972), defined as a 50% reduction in the difference between maximum strength (score of 90) and the patient's baseline score (if baseline score is <85) OR
    • 75% reduction in cutaneous lesions using the Dermatomyositis Skin Severity Index (DSSI) if baseline score is > 2


Key Trial Dates:

Start of Enrollment - 12/17/2004
Study Completion - 8/28/2007


Funding Sources:

Genentech, Inc.



David Fiorentino, M.D., Ph.D.
Assistant Professor of Dermatology
Stanford University School of Medicine
North Campus Outpatient Center
450 Broadway, C-234
Redwood City, CA 94063
Tel (650) 721-7160


Return to Therapeutic Studies listing

Back to Top